At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Contrast-enhanced MRA - Imaging examinationother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intra-individual Efficacy Evaluation of DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Lower Limb Arterial Diseases
In Brief
A Phase 4 clinical trial evaluating Contrast-enhanced MRA - Imaging examination for Peripheral Arterial Disease. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study is an intra-individual comparison of DOTAREM®-enhanced MRA and GADOVIST®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedAug 2009
Primary CompletionJun 2010
Study CompletionOct 2010
TodayJul 2026
First PostedAug 10, 2009
Enrollment StartJul 1, 2009
Primary CompletionJun 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.9 years ago
Interventions
Contrast-enhanced MRA - Imaging examinationother
Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)